NPI: 1417925025 · OCALA, FL 34481 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 03/09/2006
Authorized official WEY, SAMUEL controls 20+ related entities in our dataset. Read more
| Authorized Official | WEY, SAMUEL (VP, LICENSURE & CERTIFICATION) |
| NPI Enumeration Date | 03/09/2006 |
Other providers sharing the same authorized official: WEY, SAMUEL
| Provider | City | State | Total Paid |
|---|---|---|---|
| DVA HEALTHCARE RENAL CARE INC | NORTH HOLLYWOOD | CA | $16.47M |
| DVA HEALTHCARE RENAL CARE INC | DELANO | CA | $16.43M |
| DVA RENAL HEALTHCARE INC | LOS ANGELES | CA | $15.51M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $14.93M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.67M |
| DVA RENAL HEALTHCARE INC | OAKLAND | CA | $13.42M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.25M |
| DVA HEALTHCARE RENAL CARE INC | YUMA | AZ | $12.88M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $12.77M |
| DVA RENAL HEALTHCARE INC | FULLERTON | CA | $12.19M |
| DVA HEALTHCARE RENAL CARE INC | POMONA | CA | $11.96M |
| DVA RENAL HEALTHCARE INC | ANAHEIM | CA | $11.32M |
| DVA RENAL HEALTHCARE INC | ESCONDIDO | CA | $10.94M |
| DVA HEALTHCARE RENAL CARE INC | COSTA MESA | CA | $10.08M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $9.46M |
| DVA RENAL HEALTHCARE INC | VISALIA | CA | $9.22M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $8.83M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $8.56M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $7.78M |
| DVA RENAL HEALTHCARE INC | PALM SPRINGS | CA | $7.48M |
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 18,242 | $4.01M |
| 2019 | 19,456 | $3.83M |
| 2020 | 24,221 | $3.62M |
| 2021 | 14,343 | $1.04M |
| 2022 | 4,633 | $559K |
| 2023 | 723 | $170K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 27,290 | 1,210 | $4.41M |
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 23,014 | 1,562 | $3.61M |
| J1270 | Injection, doxercalciferol, 1 mcg | 15,605 | 1,037 | $2.62M |
| A4657 | Syringe, with or without needle, each | 2,927 | 1,265 | $736K |
| J1756 | Injection, iron sucrose, 1 mg | 4,282 | 754 | $511K |
| 85041 | 1,355 | 904 | $209K | |
| 85048 | 1,354 | 903 | $208K | |
| 83550 | 1,345 | 884 | $204K | |
| 83540 | 1,343 | 882 | $204K | |
| 82728 | 1,356 | 884 | $202K | |
| 83970 | 1,106 | 748 | $193K | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 394 | 183 | $69K |
| 82746 | 55 | 41 | $15K | |
| 82607 | 57 | 43 | $15K | |
| G0008 | Administration of influenza virus vaccine | 60 | 45 | $14K |
| 90674 | 57 | 44 | $13K | |
| 82947 | 18 | 13 | $877.84 |